Ibogaine by David Dardashti Takes Center Stage on Day One of Psychedelic Science Conference 2025, Emphasizing Collaboration, Education, and Industry Synergy
DENVER, CO - June 19, 2025 - Ibogaine by David Dardashti, a leading initiative in ibogaine research and advocacy, today commenced its participation in the highly anticipated Psychedelic Science Conference 2025 in Denver, Colorado. As the conference officially began its main programming today, June 18th, the presence of Ibogaine by David Dardashti marks a pivotal moment for the burgeoning field of psychedelic medicine, championing a collaborative approach to advance ibogaine's therapeutic potential, particularly in the realm of addiction treatment.
On this crucial first day of the conference, which runs from June 16-20, 2025 (with workshops on June 16th and 17th preceding the main conference), representatives of Ibogaine by David Dardashti are engaging with a diverse array of stakeholders, focusing on three key areas: potential collaborations with integration-based psychedelic therapies, offering internship opportunities to students of psychedelic studies, fostering synergy with other industries for enhanced news exposure within the psychedelic sub-sector.
"The future of psychedelic medicine, especially ibogaine, lies in our collective ability to integrate these powerful experiences into comprehensive, supportive care models," stated David Dardashti, the driving force behind Ibogaine by David Dardashti. "Our discussions here at Psychedelic Science 2025 are centered on forging partnerships with organizations dedicated to integration-based therapies. It's not enough to simply administer a compound; we must ensure individuals receive the robust psychological and spiritual support necessary to process and implement the profound insights gained from their ibogaine journeys."
Recognizing the critical need for a skilled workforce in this evolving field, Ibogaine by David Dardashti is also actively promoting internship opportunities for students pursuing psychedelic studies. "The next generation of researchers, therapists, and advocates will be instrumental in shaping the trajectory of psychedelic medicine," Dardashti emphasized. "We are committed to providing hands-on experience and mentorship to talented students, empowering them to contribute meaningfully to this vital area of healthcare." These internships aim to bridge the gap between academic learning and practical application, offering students invaluable exposure to clinical research, patient care, and policy development related to ibogaine.
Furthermore, Ibogaine by David Dardashti is keen to expand the reach and understanding of ibogaine within the broader public discourse. The initiative is exploring collaborations with media and other industries to facilitate greater news exposure for the psychedelic sub-sector. "Accurate and responsible media representation is paramount to dispelling misconceptions and fostering public acceptance of psychedelics as legitimate therapeutic tools," Dardashti noted. "By partnering with key industry players, we can ensure that the scientific advancements and profound patient stories surrounding ibogaine receive the attention they deserve, moving beyond sensationalism to substantive reporting."
The engagements of Ibogaine by David Dardashti at Psychedelic Science 2025, particularly on this opening day of the main conference, underscore its commitment to fostering a holistic and collaborative ecosystem for ibogaine's integration into mainstream medicine. The initiative's vision extends beyond singular research efforts, encompassing a comprehensive strategy for patient support, professional development, and public education, all crucial elements for the responsible and effective rollout of psychedelic-assisted therapies.
About Ibogaine by David Dardashti:
Ibogaine by David Dardashti is a renowned initiative led by David Dardashti, dedicated to exploring ibogaine's potential in treating addiction and other mental health challenges. With a deep commitment to ethical practices and patient well-being, the initiative champions a holistic approach to psychedelic therapy, emphasizing the importance of integration and ongoing support.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
42 minutes ago
- Globe and Mail
U.S. judge blocks National Science Foundation from slashing universities' federal funding
A federal judge on Friday prevented the National Science Foundation from sharply cutting research funding provided to universities in the latest legal setback to efforts by U.S. President Donald Trump's administration to slash government support of research at major academic institutions. U.S. District Judge Indira Talwani in Boston invalidated a policy NSF adopted in May that limited the ability of universities to be reimbursed for administrative and facility costs that indirectly support grant-funded research, ruling that it was 'arbitrary and capricious.' Spokespeople for NSF and the White House did not immediately respond to requests for comment on the ruling. NSF, a US$9 billion agency that funds scientific research, adopted the policy after having already canceled hundreds of grants out of step with the Republican president's priorities. His administration has also been freezing billions of dollars in government funding for numerous universities, including Harvard. NSF's policy, which was announced on May 2, set a cap on how much grant funding could go to cover indirect costs. NSF said funding for such costs could equal no more than 15% of the funding for direct research costs, regardless of what the costs actually were at universities. Historically, universities had negotiated with NSF and other agencies over the rate at which indirect costs could be reimbursed. The cap meant that for every $100 in funding going directly to a research grant award, universities would receive just $15 to cover overhead, such as the costs of maintaining lab space and paying for electricity and staff. The Trump administration said it sought through the policy to rein in spending on administrative overhead, which had grown to consume US$1.07 billion of NSF's annual US$4.22 billion grant-making budget for higher education institutions. That rate, though, is significantly lower than the indirect cost that many of the 69 research universities belonging to Association of American Universities had negotiated, which was often in the 50 per cent to 65 per cent range, the group's lawyers said. Talwani, an appointee of Democratic President Barack Obama, said in her Friday decision that the administration's 15 per cent rate was unlawful. The association along with two other academic trade groups and 13 schools sued in May to block the policy, after earlier convincing judges in Boston to block similar funding cuts at the National Institutes of Health and U.S. Department of Energy. The association did not immediately respond to a request for comment on the Friday decision. Among the schools that challenged NSF's funding cuts were the Massachusetts Institute of Technology, Princeton University, Brown University, the University of California, Carnegie Mellon University, Cornell University, the University of Michigan and the University of Pennsylvania. They argued that NSF's action, if allowed to stand, 'will badly undermine scientific research at America's universities and erode our nation's enviable status as a global leader in scientific research and innovation.' The U.S. Department of Defense has since also adopted a 15 per cent cap, which a judge on Tuesday temporarily blocked pending a hearing on July 2. He did so a day after a different judge in Boston ordered NIH to reinstate hundreds of grants for research on diversity-related topics nixed as part of the administration's purge of initiatives viewed as supporting 'diversity, equity and inclusion.'
Globe and Mail
4 hours ago
- Globe and Mail
Obesity Clinical Trials Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Obesity Pipeline Insigh t 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report Key Takeaways from the Obesity Pipeline Report In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus. In June 2025, Zomagen Biosciences Ltd. conducted a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. In June 2025, Boehringer Ingelheim organized a study is to find out whether a medicine called survodutide (BI 456906) helps people living with obesity disease to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. In June 2025, Novo Nordisk A/S announced a study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. In June 2025, Hanmi Pharmaceutical Company Limited conducted a phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus. DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment. The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies Obesity Emerging Drugs Survodutide: Zealand Pharma Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity. Ecnoglutide: Sciwind Biosciences Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity. CT-868: Carmot Therapeutics CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity. DD01: D&D Pharmatech DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). The Obesity pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment. Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market. Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs Obesity Companies Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Obesity Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives Scope of the Obesity Pipeline Report Coverage- Global Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Obesity Overview Obesity Pipeline Therapeutics Obesity Therapeutic Assessment Late Stage Products (Phase III) Survodutide: Zealand Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) CT-868: Carmot Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DD01: D&D Pharmatech Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Obesity Products Obesity Key Companies Obesity Key Products Obesity Unmet Needs Obesity Market Drivers Obesity Market Barriers Obesity Future Perspectives and Conclusion Obesity Analyst Views Obesity Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
4 hours ago
- Globe and Mail
Dr. Konstantinos Zarkadas Launches National Scholarship to Empower Aspiring Medical Leaders
Transformative Initiative Offers Financial Support to Future Physicians Committed to Service and Excellence GLEN COVE, NEW YORK - June 20, 2025 - In a bold step toward fostering the next generation of compassionate, driven medical professionals, Dr. Konstantinos Zarkadas, a respected leader in the healthcare sector, proudly announces the inauguration of the Dr. Konstantinos Zarkadas Scholarship for Future Doctors. This prestigious national scholarship aims to identify, support, and inspire undergraduate students who exhibit exceptional academic ability, a deep commitment to medicine, and a dedication to improving community health outcomes. The scholarship will award a one-time $1,000 grant to a single undergraduate student who meets the rigorous eligibility criteria. Applications are now open, with the deadline set for November 15, 2025. The recipient will be publicly announced on December 15, 2025. 'The future of medicine depends on individuals who lead with both intellect and empathy,' said Dr. Konstantinos Zarkadas. 'Through this scholarship, I hope to ease the financial burdens faced by aspiring doctors while encouraging them to embrace the calling of medical service with integrity, leadership, and vision. This is not just an award—it is an investment in the future of healthcare.' Dr. Zarkadas brings over two decades of experience in clinical practice and medical leadership. His academic journey, which includes a degree in Psychology from Hunter College, advanced medical training in the Dominican Republic, and a Master of Health Administration from Columbia University, has shaped his unique perspective on holistic and inclusive healthcare delivery. Currently serving as Chief Medical Officer at Arch Sleep Apnea Solutions and leading multiple medical practices, Dr. Konstantinos Zarkadas is deeply committed to transforming community health through culturally competent and patient-centered care. The Dr. Konstantinos Zarkadas Scholarship for Future Doctors has been thoughtfully designed to recognize students who combine academic excellence with a strong sense of social responsibility. Eligible applicants must meet the following criteria: Current Undergraduate Enrollment: Students must be enrolled at an accredited U.S. college or university. Pre-Medical Focus: Candidates must be pursuing a pre-med track or a closely related field, with clear intent to enter medical school. Academic Performance: A minimum cumulative GPA of 3.5 is required. Residency: Open to U.S. citizens and permanent residents. Leadership and Service: Applicants should demonstrate leadership potential and a history of meaningful community involvement. Commitment to Medicine: Candidates must clearly articulate their passion for medicine and dedication to a career in healthcare. Fluent in English, Greek, and Spanish, Dr. Konstantinos Zarkadas has long been an advocate for health equity and multicultural competence in medical practice. His past collaborations with organizations like Somos Community Care ACO and his leadership role in medical education at The New Parkway Hospital underscore his unwavering mission to mentor and empower the next wave of healthcare providers. Unlike many geographically limited programs, this scholarship is open to qualified students nationwide. Applicants must submit an original essay reflecting on their motivation to pursue medicine, their experiences in community service, and their vision for contributing meaningfully to the healthcare field. This narrative component is central to the selection process, allowing students to highlight not only their achievements but their potential for lasting impact. Comprehensive application guidelines and submission instructions can be found at: By championing students who exemplify both academic rigor and humanitarian values, the Dr. Konstantinos Zarkadas Scholarship for Future Doctors seeks to elevate the standards of tomorrow's medical profession. This initiative affirms Dr. Zarkadas's enduring belief that investing in education and ethical leadership is the surest path to a stronger, more inclusive American healthcare system. Media Contact Company Name: Dr. Konstantinos Zarkadas Scholarship Contact Person: Dr. Konstantinos Zarkadas Email: Send Email City: GLEN COVE State: NEW YORK Country: United States Website:
